1. Home
  2. RERE vs IRWD Comparison

RERE vs IRWD Comparison

Compare RERE & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATRenew Inc.

RERE

ATRenew Inc.

HOLD

Current Price

$4.87

Market Cap

859.3M

ML Signal

HOLD

Logo Ironwood Pharmaceuticals Inc.

IRWD

Ironwood Pharmaceuticals Inc.

HOLD

Current Price

$3.05

Market Cap

741.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RERE
IRWD
Founded
2011
1998
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
859.3M
741.8M
IPO Year
2021
2009

Fundamental Metrics

Financial Performance
Metric
RERE
IRWD
Price
$4.87
$3.05
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$4.94
AVG Volume (30 Days)
1.3M
3.1M
Earning Date
03-11-2026
05-06-2026
Dividend Yield
1.95%
N/A
EPS Growth
N/A
1400.00
EPS
N/A
0.15
Revenue
N/A
$298,276,000.00
Revenue This Year
$26.81
$57.95
Revenue Next Year
$22.92
$4.39
P/E Ratio
$34.57
$21.57
Revenue Growth
N/A
8.88
52 Week Low
$2.00
$0.55
52 Week High
$6.47
$5.78

Technical Indicators

Market Signals
Indicator
RERE
IRWD
Relative Strength Index (RSI) 36.92 32.58
Support Level $3.87 $1.38
Resistance Level $4.89 $3.92
Average True Range (ATR) 0.29 0.24
MACD -0.07 -0.03
Stochastic Oscillator 4.05 3.37

Price Performance

Historical Comparison
RERE
IRWD

About RERE ATRenew Inc.

ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Share on Social Networks: